Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis.
Shunsaku NakagawaMayumi NakaishiMotomu HashimotoHiromu ItoWataru YamamotoRan NakashimaMasao TanakaTakao FujiiTomohiro OmuraSatoshi ImaiTakayuki NakagawaAtsushi YonezawaHirohisa ImaiTsuneyo MimoriKazuo MatsubaraPublished in: PloS one (2018)
For the optimum efficacy of disease-modifying anti-rheumatic drugs (DMARDs), patients need to be adherent to their medication regimen. To clarify the effects of medication adherence on disease activity in Japanese patients with rheumatoid arthritis (RA), we conducted a cohort study in patients with various stages of RA. Patients were enrolled from the Kyoto University RA Management Alliance cohort, and followed up prospectively for 12 months. In this study, a total of 475 patients were analyzed and divided into 9 groups according to their medication adherence and the RA disease duration. The primary outcomes were based on the rate of a disease flare. The secondary outcomes were the changes in disease activity score using 28 joints (DAS28-ESR), simplified disease activity index (SDAI) and physical disability by health assessment questionnaire-disability index (HAQ). The changes in DAS28-ESR, HAQ, and the risk of disease flare in the highly adherent patients were significantly lower than those of the less adherent patients among the groups with RA ≤ 4.6 years but not those among the other groups. Taken together, this study identified a significant association between medication adherence and the disease flare during early-stage RA or short disease duration. These results emphasize the need to pay more attention to medication adherence in preventing the disease progression of RA.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- ankylosing spondylitis
- rheumatoid arthritis patients
- end stage renal disease
- newly diagnosed
- ejection fraction
- early stage
- healthcare
- juvenile idiopathic arthritis
- mental health
- type diabetes
- public health
- metabolic syndrome
- emergency department
- interstitial lung disease
- risk assessment
- neoadjuvant chemotherapy
- patient reported
- health insurance
- drug induced
- human health
- clinical evaluation